CNBX
CNBX Pharmaceuticals Inc.0.0004
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
221.58KP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q1 FY2026 results
CNBX Pharmaceuticals posted a Q1 FY2026 net loss of $113,719 for the quarter ended November 30, 2025, up from $34,352 y/y, driven by higher general and administrative expenses of $64,002 (versus $36,837 y/y) tied to salary increases and financial losses of $49,717 from loan interest (versus $2,485 income y/y). Operating loss widened to $64,002 from $36,837 y/y, with the net-operating gap due to interest expenses. Cash dwindled to $7,703 from $15,111 q/q after $47,408 in operating use, offset by a $40,000 short-term loan; convertible debt stood at $1.2M while related-party payables hit $1.3M. Shares outstanding ballooned to 754M from 554M q/q via $37k loan conversions. Cash burn persists. Institutional investor forbearance holds through February 2026.
10-K
FY2025 results
CNBX Pharmaceuticals posted FY2025 net loss of $313,976, down from $695,198 in FY2024, on zero revenue after $130k lab services the prior year. Operating expenses crashed 62% to $272k, driven by slashed salaries and zero R&D spend versus $195k, while cash burn eased to $171k from $244k. Convertible loans funded $160k inflows amid $1.2M related-party debt; shares exploded 17x to 554M on $298k conversions (derived). No capex, dividends, or guidance disclosed. Auditors flag going concern doubts. Thin team eyes 2026 trials, but funding drought stalls momentum.
10-Q
Q3 FY2025 results
CNBX Pharmaceuticals posted a narrower Q3 net loss of $59,727 versus $130,632 y/y, while nine-month loss shrank to $163,867 from $634,614, driven by slashed operating expenses—down to $40,380 from $152,278 q/q and $141,960 from $660,680 y/y—as R&D and G&A activities wound down. No revenues either quarter or y/y. Cash dwindled to $13,648 from $26,416, with operating cash burn at $142,760 partly offset by $129,992 in convertible loans; convertible debt stood at $1,340,136 alongside $1,174,645 due to related parties. Shares outstanding tripled to 92.5 million via loan conversions, aligning with $0.00 diluted EPS. Cash is tight.
10-Q
Q2 FY2025 results
CNBX Pharmaceuticals narrowed its Q2 FY2025 net loss to $69,788 from $325,459 y/y, while six-month loss shrank to $104,140 from $503,982, thanks to slashed operating expenses from $240,845 to $64,743 (q/q) and zero R&D spend versus $107,199 prior year—cash constraints hit hard, yet burn eased. No revenue emerged, mirroring six-month YTD zero. Cash climbed to $45,675 on $110,000 convertible loan proceeds, funding $90,741 operating outflow; convertible loans swelled to $1.4M amid forbearance pacts, with $1.2M related-party debt. Equity deficit deepened to $2.6M. Shares outstanding. Funding remains precarious.
8-K
Secures $55K convertible note
CNBX Pharmaceuticals inked a 9-month convertible promissory note with 1800 Diagonal Lending on January 24, 2025, securing $55,000 upfront and up to $850,000 total, with 9% OID and 10% interest. Conversion kicks in after 180 days at 65% of market price, but prepayment demands 110-130% premiums early on. Dilution looms large.
CANF
Can-Fite Biopharma Ltd Sponsore
0.29+0.02
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
CPMD
Cannapharmarx Inc.
0.00-0.00
CYBN
Cybin Inc.
6.66+0.00
ENVB
Enveric Biosciences, Inc.
5.24-0.12
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
LBRX
LB Pharmaceuticals Inc
19.82-0.04
NBTX
Nanobiotix S.A.
22.32+0.18
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
TOVX
Theriva Biologics, Inc.
0.21+0.01